The briefing
Researchers report that sparsentan significantly reduced urinary immune and inflammatory biomarkers versus irbesartan in patients with IgA nephropathy. The findings support potential anti-inflammatory benefits of the therapy.
Original headline
Sparsentan Reduces Urinary Immune and Inflammatory Biomarkers in IgA Nephropathy